Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopeniaRalph V. Boccia, James B. Bussel, Nichola Cooper et al.|British Journal of Haematology|2020Cited by 71
Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study GroupGunnar Birgegård, Björn Andréasson, Jan Samuelsson et al.|European Journal Of Haematology|2018Cited by 37
Genetic variation in <i><scp>IL</scp>28B</i> (<i><scp>IFNL</scp>3</i>) and response to interferon‐alpha treatment in myeloproliferative neoplasmsMarie Lindgren, Björn Andréasson, Lars Nilsson et al.|European Journal Of Haematology|2018Cited by 23
A Retrospective Cohort Study of Interferon-α Therapy in Myeloproliferative Neoplasms; Adverse Events, Thromboembolic Incidence and Causes of Termination of TherapyMarie Lindgren, Björn Andréasson, Jan Samuelsson et al.|Blood|2014Cited by 3
Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) PatientsRalph V. Boccia, James B. Bussel, Michael Boxer et al.|Blood|2019Cited by 3